urticaria

Reading File

Now I'll search the medical library for urticaria content in parallel.

Finding Sources

Searching Images

urticaria hives wheals skin

A series of three clinical photographs demonstrating the dermatological resolution of urticaria (hives) across three anatomical regions: the knee joint (A), the lateral waist (B), and the elbow (C). The images show characteristic wheals—edematous, circumscribed, and slightly elevated skin lesions. Panel A displays the knee area with subtle, flesh-colored to slightly erythematous elevations and an uneven skin texture consistent with resolving wheals. Panel B shows the lateral waist with faint, linear, and confluent dermal edema. Panel C depicts the elbow where the lesions have largely flattened, leaving only minimal, faint markings on the skin surface. The progression illustrates the transient nature of urticarial lesions as they gradually diminish in size and elevation. This visual serves as an educational reference for identifying skin morphology in the recovery phase of an acute urticarial reaction, emphasizing the characteristic lack of secondary skin changes (such as scaling or scarring) during the resolution of wheals.

A clinical photograph showing a close-up of a child's lower extremity demonstrating urticaria. The image displays multiple raised, edematous skin lesions known as wheals or hives. These lesions are characterized by pale-to-skin-colored central swellings of varying sizes and irregular shapes, surrounded by a distinct zone of erythema (redness). The distribution is scattered across the leg, illustrating the typical appearance of a hypersensitivity reaction or allergic response. This image serves as an educational reference for identifying cutaneous manifestations of urticaria, focusing on the morphology of superficial dermal edema and associated inflammatory flare.

Clinical photograph of a pediatric patient's bilateral lower limbs demonstrating classic urticaria (hives). The image shows multiple discrete and confluent wheals distributed across the thighs. Morphologically, the lesions are characterized by raised, edematous, superficial swellings of varying sizes. The central portions of the wheals appear pale or skin-colored, while the peripheries exhibit varying degrees of erythema. These findings represent a type I hypersensitivity reaction or mast cell degranulation, leading to dermal edema. This visual evidence is a key diagnostic clinical sign for acute urticaria, commonly used in dermatology and pediatric curricula to differentiate transient wheals from other types of papular eruptions or inflammatory skin conditions.

Searching PubMed

urticaria management guidelines

Good results. Now let me read the most comprehensive sources - Rosen's Emergency Medicine and Fitzpatrick's dermatology - in parallel.

Reading File

Good. Let me now read the Goldman-Cecil urticaria section in more detail and also get the Rosen's treatment section.

Reading File

Now let me also get the Dermatology 5e content and fetch the Rosen's clinical image.

Finding Sources

Loading Image

Let me get Harrison's classification table and Fitzpatrick's subtypes section.

Reading File

I now have excellent content from multiple authoritative textbooks. Let me compile the comprehensive answer.

Urticaria (Hives)

Urticaria - edematous wheals with erythema on the arm

Fig. Urticaria: edematous plaques with pale centers and red borders (Rosen's Emergency Medicine)

Definition

Urticaria (hives) is one of the most common cutaneous reaction patterns, characterized by circumscribed, raised, pruritic, evanescent areas of edema involving the superficial dermis - known as wheals. A wheal can appear reddish or whitish depending on the degree of edema. The spectrum ranges from simple wheals to angioedema (deep dermis/subcutaneous involvement). About 15-20% of the population experiences urticaria at some point in their lifetime.

Goldman-Cecil Medicine, p. 4300
Rosen's Emergency Medicine, p. 2413

Classification

By Duration

	Acute	Chronic
Duration	< 6 weeks	≥ 6 weeks
Common causes	Drugs, foods, infections, vaccines	Spontaneous/idiopathic, autoimmune, physical
More common in	Children (atopic dermatitis)	Women 20-40 years old

Chronic urticaria is further divided into:

Chronic Spontaneous Urticaria (CSU): no identifiable trigger (66-93% of chronic cases)
Inducible/Physical Urticaria: provoked by specific physical stimuli

Chronic Urticaria Types (Harrison's Table 363-1)

Acute triggers: drugs (NSAIDs, antimicrobials, ACE inhibitors, opioids, radiocontrast), foods, infections (viral, bacterial, parasitic), vaccine reactions, insect stings, transfusions

Chronic forms:

Spontaneous/idiopathic
Autoimmune (functional IgE autoantibodies)
Dermatographism (linear wheal from skin stroking; 2-5% of population)
Cholinergic urticaria (small 1-2 mm wheals + large erythema; triggered by heat, exercise, fever)
Pressure urticaria (sustained pressure - belt, shoulder strap)
Cold, solar, vibratory, aquagenic urticaria
Mastocytosis, urticarial vasculitis, hereditary angioedema (HAE)
Harrison's Principles of Internal Medicine 22E, p. 363
Fitzpatrick's Dermatology, Vol. 1-2

Pathophysiology

The core event is local mast cell degranulation with release of:

Histamine (primary mediator)
Slow-reacting substance of anaphylaxis (leukotrienes)
Bradykinin, kallikrein, acetylcholine

This leads to transvascular fluid extravasation and localized dermal edema.

Mechanisms

Immunologic:
- IgE-mediated (Type I hypersensitivity)
- Autoimmune (functional IgG autoantibodies against IgE or FcεRI)
- Immune complex-mediated
- Complement-kinin dependent
Non-immunologic:
- Direct mast cell degranulation (drugs like opioids, aspirin, foods like strawberries/lobster)
- Vasoactive stimuli

Goldman-Cecil Medicine, p. 4302
Rosen's Emergency Medicine, p. 2413

Common Causes

Category	Examples
Drugs	Penicillin, aspirin/NSAIDs (most common); also opioids, ACE inhibitors, radiocontrast
Foods	Seafood, tree nuts, eggs, peanuts (IgE-mediated); strawberries, lobster (direct histamine release)
Infections	Rhinovirus, rotavirus, hepatitis, EBV (mono), Coxsackievirus; Candida, dermatophytes, parasites
Physical	Cold, heat, pressure, sun, vibration, water, exercise
Contact	Foods, animal dander/saliva, plants, topical medications, cosmetics, chemicals

Note: Penicillin traces may persist in dairy products and other medications. Aspirin's mechanism is likely non-immunologic and effects can persist for weeks.

Clinical Features

Wheals: Edematous plaques, pale center + red border ("wheal and flare"), blanching on pressure
Pruritus: Hallmark symptom
Evanescent: Individual lesions typically last < 24 hours (this is a key diagnostic feature)
New lesions continuously develop while old ones resolve
May coexist with angioedema (deeper swelling - face, lips, tongue, throat)
Angioedema without wheals occurs in 1-13% of CSU patients

Differential Diagnosis

Drug eruption / viral exanthem
Erythema multiforme
Erythema marginatum
Urticarial vasculitis (lesions persist > 24h, may bruise)
Juvenile rheumatoid arthritis
Bullous pemphigoid (urticarial stage)
Neutrophilic urticaria
Mastocytosis

Key differentiating feature: True urticaria resolves within 24 hours without residual skin changes (no bruising, scaling, or scarring).

Fitzpatrick's Dermatology, p. 46
Rosen's Emergency Medicine, p. 2413

Management

Step 1: Remove the trigger

Identify and eliminate the causative agent when possible.

Step 2: Antihistamines (First-line)

H1 antihistamines (preferred non-sedating): Cetirizine, fexofenadine, loratadine
Sedating H1: Hydroxyzine (useful for pruritus relief)
H2 blocker addition: Can be added in chronic or refractory cases (e.g., ranitidine, famotidine)
For chronic urticaria: long-term combination H1+H2 antihistamines

Step 3: Corticosteroids (Adjunctive)

Moderate/severe urticaria: prednisone or dexamethasone
Recurrent urticaria: 14-21 day course with taper
Chronic steroid use is not recommended

Step 4: Advanced/Refractory Therapy

Omalizumab (anti-IgE monoclonal antibody): highly effective for chronic spontaneous urticaria - a 2025 meta-analysis confirms its efficacy and safety in pediatric CSU as well
Cyclosporine: second-line immunosuppressant for CSU
A 2024 systematic review on acute urticaria treatment found that antihistamines remain the cornerstone, with corticosteroids as adjuncts
Rosen's Emergency Medicine, p. 2414
Goldman-Cecil Medicine, p. 4302

Special Considerations

Situation	Notes
Angioedema with airway compromise	Treat as anaphylaxis: epinephrine IM, airway management
Chronic spontaneous urticaria	Half of patients have disease for 5+ years; investigate for autoimmune cause
Dermatographism	Usually resolves within 5 years; reassurance + antihistamines
Cholinergic urticaria	Avoid triggers (heat, exercise); H1 antihistamines ± beta-blockers
Cold urticaria	Risk of anaphylaxis with cold water immersion; carry epinephrine
Pressure urticaria	Often accompanies CSU; responds poorly to antihistamines

Key Points for Boards/Exams

Urticaria lasting < 6 weeks = acute; ≥ 6 weeks = chronic
Individual wheals resolve in < 24 hours - if they persist longer, consider urticarial vasculitis
Most common drugs: penicillin and aspirin
Most chronic urticaria is idiopathic/spontaneous
First-line: non-sedating H1 antihistamines
Refractory CSU: omalizumab (anti-IgE)
Angioedema of the larynx/tongue = emergency - epinephrine

Types of Give me detailed notes about urticaria

Searching sources...

Finding Sources

Searching Images

urticaria types wheals angioedema dermatographism cholinergic

Clinical photography of a patient with cholinergic urticaria showing multiple small, erythematous, blanching wheals on the forearm. Imaging modality is clinical photography; technique involves a high-resolution, color-balanced image capturing superficial skin lesions in a macro-clinical view. The wheals are transient, pruritic, and vary in size from a few millimeters to up to several millimeters, with well-demarcated borders and pale centers. Triggered by heat, exercise, and emotional stress, the lesions can appear soon after sweating and typically resolve within minutes to hours. This presentation correlates with cholinergic urticaria, a physical urticaria subtype linked to cholinergic stimuli, requiring history of triggers and symptom timing. Differential diagnoses include other urticarias and heat-induced dermatoses; diagnostic significance lies in distinguishing exercise/sweat-induced wheals from dermatographism or drug reactions to guide management. Clinical utility includes educating patients on trigger mitigation, optimizing antihistamine therapy, and evaluating for underlying mast cell disorders if atypical features arise. Chronic management includes non-sedating H1 antihistamines at standard or increased dosing, with occasional H2 blockade. Patients are advised to avoid overheating, wear breathable clothing, and perform graded exercise; epinephrine is reserved for rare anaphylaxis. In ambiguous cases, exercise-provoked challenges or sweat tests may help; history differentiates from other physical urticarias.

This is a dermatology clinical photograph of the skin surface demonstrating the typical small, transient wheals seen in cholinergic urticaria. The image shows numerous pinpoint to 3–4 mm erythematous, raised plaques scattered across the forearm in a crops-like distribution. Each wheal shows central blanching with a slightly edematous, ring-like border and a blanching halo consistent with superficial dermal edema. The lesions are pruritic and short-lived, usually resolving within 1–2 hours, often appearing after heat exposure, exercise, or emotional stress. In cholinergic urticaria, symptoms may be accompanied by warmth, sweating, or mild warmth-induced flushing. The focal photodermatographic appearance is not necessarily specific but the small size, rapid onset following provocative stimuli, and distribution pattern strongly support a physical urticaria rather than mast cell neoplasia or dermatitis. Clinically relevant features include the ability to trigger crops, readiness to respond to oral antihistamines, and potential improvement with pre-exercise cooling or preventive antihistamine therapy. The differential diagnosis includes other physical urticarias (dermographism, heat urticaria), ordinary urticaria, papular urticaria, and less commonly urticarial vasculitis. This image is most useful for educational illustration of cholinergic urticaria triggers: exercise, heat, stress; and for training in clinical recognition and patient counseling.

Clinical photograph of bilateral forearms showing multiple discrete 5 mm erythematous, blanchable wheals consistent with cholinergic urticaria precipitated by exercise. Lesions are superficial, well defined, round-to-oval, slightly raised, and distributed patchily across extensor surfaces of the forearms. The wheals appear shortly after exertion or warm ambient conditions and resolve within minutes to an hour, often preceding or accompanying mild pruritus. The image demonstrates a transient urticarial eruption without mucosal involvement or vesiculation. From a pathophysiologic perspective, cholinergic urticaria results from mast cell degranulation and histamine release triggered by increased core temperature and sweating; histologic findings (if biopsy were available) would show dermal edema with perivascular inflammatory infiltrate rich in eosinophils. Clinically, these findings aid differentiation from other physical urticarias such as heat urticaria, solar urticaria, or pressure urticaria, and from non-urticarial pruritic eruptions. This photograph supports diagnostic consideration in patients with exercise-induced pruritic wheals and provides material for education on recognition, documentation, and management planning. Relevance spans dermatology, allergology, pediatrics, and sports medicine; can guide antihistamine therapy, pre-exercise prophylaxis, and patient counseling on trigger avoidance and skin care during heat stress. Documentation of such patterns supports longitudinal monitoring and therapeutic response assessment.

Clinical photograph of a left forearm demonstrating dermatographism (skin writing), a form of physical urticaria. The image shows three distinct, raised, linear wheals (urticarial lesions) running longitudinally along the forearm. These markings are characteristically pale or erythematous with well-defined borders against the surrounding skin. The appearance is a classic representation of the triple response of Lewis, specifically the localized edema (wheal) that occurs in response to firm stroking or mechanical pressure on the skin. This finding is often associated with mast cell degranulation and histamine release in sensitive individuals. The photograph serves as an educational example for diagnosing physical urticarias and understanding the cutaneous manifestations of hyperreactivity in the dermatology and allergy/immunology domains.

Reading File

Excellent. Now let me get the detailed physical urticaria subtypes from Andrews' and the chronic spontaneous/autoimmune details from Fitzpatrick's.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have all the detailed content needed. Let me also fetch the dermatographism and cholinergic images.

Loading Image

Detailed Notes on Types of Urticaria

Master Classification Framework

Urticaria is classified by two axes: duration and trigger.

URTICARIA
├── SPONTANEOUS
│   ├── Acute Spontaneous (<6 weeks)
│   └── Chronic Spontaneous (≥6 weeks)
│       ├── Autoimmune
│       └── Idiopathic
└── INDUCIBLE (Physical)
    ├── Symptomatic Dermographism
    ├── Cholinergic Urticaria
    ├── Cold Urticaria
    ├── Heat Urticaria
    ├── Delayed Pressure Urticaria
    ├── Solar Urticaria
    ├── Aquagenic Urticaria
    ├── Vibratory Angioedema
    ├── Contact Urticaria
    └── Adrenergic Urticaria

SPECIAL ENTITIES
    ├── Urticarial Vasculitis
    ├── Angioedema (including HAE)
    └── Papular Urticaria

Physical/inducible urticarias account for up to 35% of all urticarias, occurring most commonly in persons aged 17-40.

Andrews' Diseases of the Skin, p. 176
Fitzpatrick's Dermatology, Vol. 1-2

PART 1: SPONTANEOUS URTICARIA

1A. Acute Spontaneous Urticaria

Feature	Details
Duration	< 6 weeks
Prevalence	Most new-onset urticaria (>2/3 of cases)
Common in	Children and young adults
Main causes	Viral URIs (most common in children), drugs (NSAIDs, antibiotics), foods, insect stings
Workup needed	Usually none; history + exam sufficient
Prognosis	Self-limited; resolves once trigger removed

Key triggers:

Infections: rhinovirus, rotavirus, EBV (mononucleosis), hepatitis B/C, Coxsackievirus, psittacosis
Drugs: penicillin, NSAIDs, opioids, radiocontrast dye, vancomycin
Foods: shellfish, peanuts, tree nuts, eggs, milk, strawberries, lobster, chocolate, tomatoes, spices
Food additives: azo dyes, benzoic acid, sulfites, tartrazine
Inhalants: grass pollen, house dust mites, animal dander, molds, formaldehyde
Andrews' Diseases of the Skin, p. 175

1B. Chronic Spontaneous Urticaria (CSU)

Feature	Details
Duration	≥ 6 weeks, occurring almost daily
Prevalence	~0.5-1% of population; 66-93% of chronic urticaria cases
Demographics	Women > men (2:1); peak age 20-40 years
Cause identified	< 20% of cases; majority remain idiopathic
Duration of disease	50% have symptoms ≥ 5 years

Associated features:

Wheals + angioedema: 33-67% of CSU patients
Wheals only: 29-65%
Angioedema only: 1-13%
Flower-like or annular-shaped wheals are characteristic
Stress and fatigue are common aggravating factors; depression/anxiety are comorbidities

Investigations for CSU:

Routine: CBC with differential, ESR or CRP
Extended (based on history): H. pylori testing, thyroid antibodies (anti-TPO, anti-Tg), autologous serum skin test (ASST), tryptase (rule out mastocytosis), allergy skin tests, skin biopsy
Fitzpatrick's Dermatology, p. 717-723
Harrison's 22E, p. 2852

1C. Autoimmune Urticaria (subset of CSU)

Feature	Details
Prevalence	Up to 45% of chronic urticaria patients
Mechanism	IgG autoantibodies against IgE or against the alpha chain of the high-affinity IgE receptor (FcεRI)
Detection	Autologous serum skin test (ASST): inject patient's own serum intradermally → positive wheal-and-flare
Basophil testing	Autoantibodies induce CD63 or CD203c expression on basophils (activation markers)
Associated conditions	Hashimoto's thyroiditis (euthyroid or clinical), SLE
Response to Rx	Often requires omalizumab or cyclosporine; antihistamines alone frequently insufficient

Harrison's Principles of Internal Medicine 22E, p. 2851

PART 2: INDUCIBLE (PHYSICAL) URTICARIAS

2A. Symptomatic Dermographism (Urticaria Factitia)

Dermatographism: linear wheals from skin stroking

Feature	Details
Definition	Linear wheal + erythema at site of a brisk stroke with a firm object
Prevalence	2-5% of population; most common inducible urticaria
Demographics	Peak in 2nd-3rd decades; not influenced by atopy
Mechanism	Mast cell degranulation (piecemeal/zonal pattern) with histamine release
Duration of disease	Generally < 5 years
Provocation test	Stroke skin firmly (e.g., tongue blade) - wheal appears within minutes
Treatment	H1 antihistamines (first-line); threshold testing to gauge response

Also called: "skin writing" - the word "urticaria" can be literally written on the skin.

Harrison's 22E, p. 2850; Andrews' Diseases of the Skin

2B. Cholinergic Urticaria

Cholinergic urticaria: tiny punctate wheals with large erythematous flare

Feature	Details
Trigger	Rise in core body temperature (exercise, hot bath/shower, fever, emotional stress)
Morphology	Minute 1-3 mm wheals surrounded by large erythematous flare - very distinctive
Location	Primarily trunk and face; spares palms and soles
Duration	Lesions persist 30-90 min; followed by refractory period up to 24 hours
Mechanism	Acetylcholine acts on mast cells; ~2/3 of patients have IgE antibodies to sweat antigens
Complications	Bronchospasm may occur; familial cases reported
Provocation test	Exercise or warm bath raising core temperature by 0.7-1.0°C
Abort an attack	Rapid cooling (cold shower) may abort an attack

Treatment:

H1 antihistamines (first-line)
Add H2 antihistamine for additional benefit
Combine with montelukast and propranolol in refractory cases
Danazol (attenuated androgen) for refractory cases
Omalizumab for severe refractory cases
Andrews' Diseases of the Skin, p. 176; Harrison's 22E

2C. Cold Urticaria

Feature	Details
Trigger	Exposure to cold air, cold water, cold objects
Key feature	Wheals develop on rewarming, NOT during cold exposure
Location	Usually localized to exposed areas (face, hands)
Life-threatening risk	Fatal anaphylaxis/shock from cold water immersion or cold shower - patients must carry epinephrine

Classification of Cold Urticaria:

Type	Features
Primary (Essential)	No underlying disease or cold-reactive proteins; begins in adulthood; localized to cold-exposed areas
Secondary	Associated with cryoglobulins, cold agglutinins (up to 5% of cases), infections (hepatitis, EBV), SLE
Familial	Rare; autosomal dominant; mutations in NLRP3 (inflammasome) → familial cold autoinflammatory syndrome

Provocation test: Ice cube placement on volar forearm - wheal/angioedema within minutes

Mechanism: Ice cube provocation shows marked mast cell degranulation + elevated histamine levels in venous effluent; pattern resembles IgE-mediated response

Treatment: Antihistamines; avoid cold exposure; carry epinephrine auto-injector; cyproheptadine is classically used

Andrews' Diseases of the Skin; Harrison's 22E, p. 2851

2D. Delayed Pressure Urticaria

Feature	Details
Trigger	Sustained pressure after a delay of 4-6 hours
Examples	Shoulder strap, belt, running (feet), manual labor (hands), sitting
Morphology	Deep, painful edematous swellings at pressure sites
Association	Frequently accompanies chronic spontaneous urticaria
Delay	Characteristic 4-6 hour delay between pressure and wheal
Treatment	Responds poorly to antihistamines; NSAIDs, dapsone, or systemic steroids sometimes needed

Diagnostic test: Apply 15 lb weight over shoulder for 15 minutes; assess 4-6 hours later

Harrison's 22E; Andrews' Diseases of the Skin

2E. Solar Urticaria

Feature	Details
Trigger	Ultraviolet (UV) or visible light exposure
Onset	Minutes after sun exposure
Resolution	Within hours of removing light source
Classification	6 subtypes based on wavelength of light causing reaction
Complications	Severe cases: systemic reaction with exposed large body surface area
Treatment	Antihistamines; photoprotection; phototherapy (hardening/tolerance induction); omalizumab

Diagnostic test: UV and visible light of different wavelengths with threshold testing (as per EAACI guidelines)

Fitzpatrick's Dermatology, Table 41-1; Harrison's 22E

2F. Heat Urticaria

Feature	Details
Trigger	Local heat application to skin
Distinction	Different from cholinergic urticaria (which is triggered by rise in core temperature; heat urticaria is local)
Provocation test	Apply warm object to skin; measure threshold temperature
Treatment	Antihistamines

2G. Aquagenic Urticaria

Feature	Details
Trigger	Contact with water at any temperature
Rare condition	Very uncommon
Association	Sometimes associated with polycythemia vera
Distinction	Different from cold urticaria (which is temperature-dependent)
Treatment	Antihistamines; barrier creams before water contact

2H. Vibratory Angioedema/Urticaria

Feature	Details
Trigger	Vibration (using vibrating machinery, running, towel drying)
Onset	Within minutes of vibration exposure
Hereditary form	Autosomal dominant; mutation in ADGRE2 gene (mast cell mechanoreceptor) - identified recently
Acquired form	After years of occupational exposure (e.g., jackhammer operators)
Association	May accompany cholinergic urticaria
Diagnostic test	Vortex mixer or vibration device applied to forearm
Treatment	Avoidance; antihistamines

Harrison's 22E, p. 2851; Fitzpatrick's Dermatology

2I. Contact Urticaria

Feature	Details
Trigger	Direct skin/mucosal contact with chemical or protein allergen
Mechanism	Immunologic (IgE-mediated) or non-immunologic
Common allergens	Latex (with cross-reactivity to chestnuts, bananas, avocado, kiwi, passion fruit), foods, plants, medications, cosmetics
Latex cross-reaction	Important to recognize - latex allergy patients may react to these foods
Treatment	Avoidance; antihistamines

2J. Adrenergic Urticaria

Feature	Details
Trigger	Emotional upset, coffee, chocolate
Morphology	Small (1-5 mm) red macules/papules with pale halo (distinguishes from cholinergic)
Onset	Within 10-15 minutes of trigger
Mechanism	Mediated by norepinephrine (not acetylcholine) - serum catecholamines elevated during attacks
Key distinction	Histamine and serotonin levels are NORMAL (unlike cholinergic)
May coexist	Can occur with cholinergic urticaria
Provocation test	Intradermal injection of 3-10 ng of norepinephrine
Treatment	Propranolol 10 mg QID (effective); atenolol is ineffective; anxiolytic benzodiazepines for refractory cases

Andrews' Diseases of the Skin, p. 176

PART 3: SPECIAL ENTITIES

3A. Urticarial Vasculitis

Feature	Details
Prevalence	5-10% of patients with "fixed" urticarial lesions
Key distinguishing features	See table below

How to distinguish from ordinary urticaria:

Feature	True Urticaria	Urticarial Vasculitis
Symptom	Pruritic	Burning or painful (not pruritic)
Duration	< 24 hours, transient	> 24 hours, fixed
Resolution	Clean	Postinflammatory purpura/hyperpigmentation
Histology	Dermal edema	Leukocytoclastic vasculitis
Antihistamine response	Good	Poor

Two forms:

Type	Features
Normocomplementemic	Limited to skin; idiopathic; self-resolving; subset of cutaneous small-vessel vasculitis
Hypocomplementemic	Almost always in women; ↓C1q, C3, C4; anti-C1q antibodies; arthritis (50-82%), angioedema, eye symptoms (56%), asthma (20%), GI symptoms (20%), glomerulonephritis; >50% eventually meet SLE criteria

Associated diseases: SLE, Sjögren syndrome, gammopathy (IgG/IgM), serum sickness, hepatitis C

Drug causes: Penicillin, cimetidine, cocaine, NSAIDs, SSRIs, SSKI, TNF-inhibitors

Workup: CH50, C3, C4, anti-C1q antibodies, ANA, anti-dsDNA, skin biopsy (essential)

Treatment:

Antihistamines (often ineffective for hypocomplementemic type)
Indomethacin (particularly effective)
Dapsone, antimalarials (hydroxychloroquine), colchicine
Pentoxifylline as add-on
Severe cases: corticosteroids, immunosuppressives, omalizumab
Andrews' Diseases of the Skin, p. 4254-4282

3B. Angioedema

Definition: Urticaria that extends into the deep dermis and subcutaneous/submucosal tissues

Two subsets:

Type	Features
Histaminergic (deep urticaria)	Solitary or multiple sites; associated with hives; pruritic; vasomotor lability; responds to antihistamines/epinephrine
Bradykinin-mediated (HAE/ACE-inhibitor)	No hives, no pruritus; pain predominates; GI involvement; lasts >24h; does NOT respond to antihistamines/epinephrine

Hereditary Angioedema (HAE):

Also called Quincke edema; originally described by Osler (1888)
Autosomal dominant; SERPING1 gene mutation; 1 in 30,000-80,000 population
Onset before age 20; attacks every 2 weeks lasting 2-5 days
Asymmetric swelling; no urticaria, no pruritus
Life-threatening: laryngeal edema (fatal if untreated)
GI attacks mimic appendicitis (can lead to unnecessary surgery)

HAE Type	C1INH Antigen	C1INH Function	C4	C1q
Type I (85%)	Low	Low	Low	Normal
Type II	Normal/High	Low	Low	Normal
Type III	Normal	Normal	Normal	Normal

Screening test of choice: C4 level (will be low in Types I and II even between attacks)

Treatment of HAE:

Acute attack: Plasma-derived or recombinant C1 inhibitor; ecallantide (kallikrein inhibitor); icatibant (bradykinin B2 receptor antagonist)
Short-term prophylaxis (pre-surgery/dental): C1 inhibitor replacement or danazol
Long-term prophylaxis: Attenuated androgens (danazol), antifibrinolytics (tranexamic acid), C1 inhibitor replacement, lanadelumab (anti-kallikrein monoclonal antibody)
Estrogens/OCPs precipitate attacks - avoid!
Antihistamines, epinephrine, corticosteroids have minimal/no effect on HAE
Andrews' Diseases of the Skin, p. 3300-3311; Harrison's 22E, p. 2852

3C. Papular Urticaria

Feature	Details
Cause	Hypersensitivity reaction to insect bites (fleas, mosquitoes, bed bugs, mites)
Common in	Children
Morphology	Pruritic papules/papulovesicles at bite sites; may be grouped
Distribution	Exposed areas (legs, arms)
Treatment	Insect avoidance, antihistamines, low-potency topical steroids

PART 4: DIAGNOSTIC TESTING SUMMARY (EAACI Guidelines)

Urticaria Subtype	Routine Test	Extended Test
Acute spontaneous	None	None (unless allergy suspected)
CSU	CBC, ESR/CRP	H. pylori, thyroid antibodies, ASST, tryptase, biopsy
Cold urticaria	Cold provocation + threshold test	Differential CBC, ESR/CRP, rule out infections
Delayed pressure	Pressure test + threshold	None
Heat urticaria	Heat provocation + threshold	None
Solar urticaria	Multi-wavelength UV/visible light testing	Rule out other photodermatoses
Dermographism	Dermographometer + threshold	CBC, ESR/CRP
Cholinergic	Exercise/heat provocation + threshold	None
Vibratory	Vortex or mixer vibration test	None
Aquagenic	Water provocation	None
Contact urticaria	Provocation at contact site	None

Source: Fitzpatrick's Dermatology (EAACI/GA2LEN/EDF/WAO 2018 Guideline), Table 41-1

PART 5: TREATMENT ALGORITHM (Step-Up Approach)

STEP 1 ─── Identify and remove trigger
            Non-sedating H1 antihistamine (cetirizine, loratadine, fexofenadine)
            [Standard dose]

STEP 2 ─── Increase H1 antihistamine up to 4x daily dosing
            Add H2 antihistamine (ranitidine/famotidine)
            Add leukotriene receptor antagonist (montelukast 10 mg/day)

STEP 3 ─── OMALIZUMAB (anti-IgE monoclonal antibody)
            [For CSU failing Steps 1-2]
            Evidence: very effective, including pediatric CSU

STEP 4 ─── CYCLOSPORINE (immunosuppressant)
            [For CSU with autoimmune component, omalizumab failure]
            Second-line immunosuppression

ADJUNCTS
  • Short course corticosteroids (prednisone 14-21 days with taper)
  • Not for chronic use
  • For HAE: C1 inhibitor / icatibant / ecallantide (NOT antihistamines)
  • For urticarial vasculitis: indomethacin, dapsone, antimalarials

Sources: Harrison's Principles of Internal Medicine 22E, p. 2852; Rosen's Emergency Medicine; Goldman-Cecil Medicine

QUICK COMPARISON TABLE: Key Inducible Urticarias

Type	Trigger	Wheal Size	Key Feature	Treatment
Dermographism	Scratching/stroking	Linear	"Skin writing"; 2-5% prevalence	H1 antihistamines
Cholinergic	Heat, exercise, fever	Tiny 1-3 mm + large flare	Spares palms/soles; refractory period	H1 ± H2, propranolol
Adrenergic	Stress, coffee, chocolate	Small 1-5 mm, pale halo	Normal histamine; high catecholamines	Propranolol
Cold	Cold exposure	Varies	Wheals on rewarming; anaphylaxis risk	Antihistamines; epinephrine
Pressure (delayed)	Sustained pressure	Deep, painful	4-6 hour delay	Steroids; dapsone
Solar	UV/visible light	Varies	6 subtypes by wavelength	Antihistamines; photoprotection
Aquagenic	Water (any temp)	Tiny punctate	Associated with polycythemia vera	Antihistamines; barrier cream
Vibratory	Vibration	Localized	ADGRE2 mutation (hereditary form)	Avoidance

Sources: Fitzpatrick's Dermatology Vol. 1-2 | Andrews' Diseases of the Skin, Clinical Dermatology | Harrison's Principles of Internal Medicine 22E | Goldman-Cecil Medicine | Rosen's Emergency Medicine

Pathology of urticaria

Searching sources...

Finding Sources

Searching Images

urticaria histology mast cell degranulation dermal edema microscopy

Imaging modality: Light microscopy of a hematoxylin and eosin stained skin biopsy (dermis). The section demonstrates a sparse dermal infiltrate of mast cells in a perivascular distribution within the superficial to mid dermis, adjacent to collagen and small vessels. Mast cells appear as round to oval basophilic nuclei with granulated cytoplasm; the background stroma shows mild edema and mild perivascular lymphocytic inflammation. The infiltrate is not dense, supporting a clinical diagnosis of urticaria pigmentosa (cutaneous mastocytosis) rather than a mast cell proliferation with extensive infiltration. The epidermis is relatively preserved; no pseudoepitheliomatous hyperplasia; no significant fibrosis. Special stains or immunohistochemistry with CD117 (c-kit) or tryptase would enhance confirmation, as normal skin contains few dermal mast cells. Clinically, this histology correlates with pruritus, flush, Darier sign, and pigmentary changes. Diagnostic significance: Supports cutaneous mastocytosis; helps differentiate from pigmented nevi or dermatitis without mast cell infiltration. Differential considerations include other forms of cutaneous mastocytosis, pigmented lesions, and inflammatory dermatoses with inflammatory infiltrates. This image is educational for dermatopathology and histology of urticaria pigmentosa, and can guide workup for systemic involvement if clinically indicated. Terminology: cutaneous mastocytosis; mast cell tryptase testing; KIT mutation assessment may follow.

This histopathology image demonstrates a dermatologic mast cell infiltrate associated with urticaria pigmentosa (cutaneous mastocytosis). Acquired lesion is evaluated on a formalin-fixed skin biopsy processed for light microscopy. The section shows dense sheets of round to oval, sometimes spindle-shaped mast cells occupying the superficial to mid-dermis. Individual cells exhibit uniform nuclei with clumped chromatin and moderate eosinophilic to amphophilic cytoplasm; cytoplasmic granules are faintly visible. The overall pattern lacks conspicuous epithelial involvement and displays a perivascular, often diffuse dermal distribution rather than compact clusters. Immunophenotypic context typically includes CD117 (c-KIT) positivity of neoplastic mast cells; aberrant CD25/CD2 expression may be present in some cases of systemic mastocytosis but is not consistently seen in reactive mast cell hyperplasia. In reactive conditions, mast cells are more loosely scattered with a perivascular tendency and are usually CD25/CD2 negative. Clinically, this histology supports a diagnosis of cutaneous mastocytosis when correlated with clinical findings such as pruritus, Darier sign, or urticarial plaques. The image is educational for dermatopathology, pathology residents, and clinicians, illustrating differential considerations with reactive mast cell hyperplasia and mastocytosis. It may guide immunohistochemical workup and subsequent systemic evaluation if warranted. for education.

This is a histopathology image of a skin biopsy stained with hematoxylin and eosin, showing a dense dermal mast cell infiltrate consistent with urticaria pigmentosa (cutaneous mastocytosis). The neoplastic mast cells are uniform, arranged in sheets within the reticular dermis, with oval to spindle-shaped morphology and ample eosinophilic or amphophilic cytoplasm containing visible granules. Nuclei are round to oval with clumped chromatin and inconspicuous nucleoli; binucleated cells may be present. Cytologic atypia is not a prominent feature, supporting a benign or indolent mast cell proliferation rather than high-grade disease. The surrounding stroma shows mild edema and occasional inflammatory cells; blood vessels are unaffected. Immunohistochemistry for CD117 (c-KIT) would typically be positive, and toluidine blue or other mast cell stains would highlight granules, confirming mast cell lineage. Clinically, this histology correlates with pigmented, pruritic lesions that characteristically degranulate on mechanical stimulation (Darier's sign). The image captures the key diagnostic features: sheets of uniform mast cells in the dermis, minimal pleomorphism, and absence of marked mitotic activity. This pattern helps distinguish cutaneous mastocytosis from reactive mast cell hyperplasia; however, assessment for systemic involvement (serum tryptase, KIT mutational status, organomegaly) may be warranted in broader clinical contexts.

Clinical photograph documenting pressure urticaria on the forearms. This in vivo, noninvasive Digital photography captures bilateral erythematous plaques and diffuse surface redness following sustained mechanical pressure. The forearms (bilateral) show symmetric involvement of the ventral/volar aspects near the antecubital region with a uniform, diffuse erythema and subtle edema without purpura or necrosis. The appearance is consistent with urticarial wheals produced by mast cell degranulation and superficial dermal edema in response to physical stimulation. The photo exemplifies a transient, pressure-induced skin reaction that typically waxes and wanes with time and relief of pressure. The imaging modality is clinical photography using a standard digital camera under ambient lighting, not contrast-enhanced, not magnified. Staining or histology are Not applicable. This image is valuable for clinical documentation, patient education, and research on physical urticarias, including pressure urticaria and dermographism. Differential considerations include allergic contact dermatitis, erythema multiforme, cellulitis, and vasculitic eruptions, all of which can mimic redness but differ in onset, warmth, and distribution. Clinical correlation with history of pressure exposure, timing, pruritus, and response to antihistamines is essential for accurate diagnosis and management planning. Images of such reactions support education, triage, and monitoring treatment outcomes in dermatology and allergy clinics for broader research.

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

Loading Image

Reading File

I now have rich, detailed pathology content. Let me also get the Robbins/Fitzpatrick pathology sections.

Reading File

Loading Image

Reading File

Excellent - I now have comprehensive pathology content with diagrams. Compiling the full detailed notes now.

Pathology of Urticaria - Detailed Notes

1. GROSS / MACROSCOPIC PATHOLOGY

The fundamental lesion of urticaria is the wheal - a result of localized dermal microvascular hyperpermeability.

Feature	Description
Morphology	Raised, edematous plaques with central pallor (pale/white center) and peripheral erythematous flare
Size	A few mm to as large as a hand; may coalesce into larger plaques
Color	Pink to pale (whiter when edema is more prominent)
Surface	Smooth; no scaling, no vesicles, no necrosis
Hallmark	Each individual lesion comes and goes within < 24 hours
Pruritus	Hallmark symptom
Angioedema	When edema extends into deep dermis/subcutaneous tissue: faint pink, painful, less defined, lasts 2-3 days

Dermatology 5e (Grattan, Kocatürk, Saini), p. 372
Robbins & Kumar Basic Pathology, p. 879

2. HISTOPATHOLOGY (Microscopic Pathology)

Classic Histologic Findings

The histologic features of urticaria are characteristically subtle - in stark contrast to the dramatic clinical appearance.

Layer	Findings
Epidermis	Normal; no spongiosis, no acanthosis
Superficial dermis	Edema - collagen bundles are widely spaced ("splaying") due to accumulated fluid
Blood vessels	Dilated postcapillary venules; endothelium normal (in ordinary urticaria)
Inflammatory infiltrate	Sparse mixed perivascular infiltrate around superficial and mid-dermal venules
Cell types	Lymphocytes (predominant), eosinophils, basophils, some neutrophils
Mast cells	Degranulated mast cells around superficial dermal venules; appear pale/empty

Key microscopic point: In routine H&E stain, mast cells are difficult to see. They are better visualized with Giemsa stain or toluidine blue (both highlight the metachromatic granules).

Robbins & Kumar Basic Pathology, p. 879
Dermatology 5e, p. 382

Histologic Variants

Variant	Microscopic Pattern	Clinical Significance
Classic/Lymphocytic urticaria	Sparse perivascular lymphocytes + mild edema	Most common; typical CSU
Neutrophilic urticaria	Predominantly neutrophilic dermal infiltrate (no vasculitis features)	May indicate autoinflammatory syndrome (CAPS, Schnitzler, Still disease, SLE)
Urticarial vasculitis	Leukocytoclastic vasculitis: endothelial damage, perivenular neutrophil-rich infiltrate, karyorrhexis (nuclear dust), fibrinoid deposits in vessel walls, erythrocyte extravasation	Hypocomplementemic form = systemic disease (SLE overlap)
Urticarial bullous pemphigoid	Eosinophil-rich infiltrate; subepidermal blister	Pre-bullous pemphigoid; lesions last >24h

Rule: If urticarial lesions consistently persist >24-36 hours, are painful rather than pruritic, and leave bruising/pigmentation on resolution → biopsy is mandatory to rule out urticarial vasculitis.

Dermatology 5e, p. 382

3. PATHOGENESIS - CELLULAR AND MOLECULAR

The Central Event: Mast Cell Degranulation

The mast cell is the primary effector cell of urticaria.

Two mast cell phenotypes in skin:

Type	Location	Contents	IgE receptor
MCTC (tryptase + chymase)	Skin, intestinal submucosa	Tryptase + chymase	Yes (FcεRI)
MCT (tryptase only)	Bowel mucosa, alveolar wall, nasal mucosa	Tryptase only	Yes (FcεRI)

Both types express FcεRI and can participate in IgE-dependent reactions. Cutaneous mast cells in urticaria are more "releasable" - they degranulate more readily in response to stimuli (e.g., intradermal codeine injection).

Step-by-Step Degranulation Mechanism

Trigger (antigen/autoantibody/physical stimulus) ↓ Cross-linking of 2+ adjacent FcεRI receptors on mast cell membrane ↓ Calcium- and energy-dependent signaling cascade (SYK → LAT → PLCγ → PKC) ↓ Fusion of storage granules with cell membrane ↓ Externalization of granule contents (degranulation) ↓ Mediator release → vasodilation + vascular permeability → edema + pruritus

Mast Cell Degranulating Stimuli

Fig. Mast cell degranulating stimuli - Dermatology 5e

Pathway	Stimulus	Receptor
Immunologic (IgE-dependent)	Allergen cross-links IgE-bound FcεRI	FcεRI
Immunologic (autoantibody)	Anti-IgE IgG, anti-FcεRI IgG	FcεRI
Complement-mediated	C5a anaphylatoxin	C5a receptor
Non-immunologic	Opioids, codeine, substance P, polymyxin B	MRGPRX2 receptor
Growth factor	Stem cell factor	KIT receptor
Physical stimuli	Cold, pressure, vibration, UV, heat	Various / indirect

4. INFLAMMATORY MEDIATORS RELEASED

Mast cell mediators diagram: preformed (histamine, heparin, tryptase/proteases) and newly synthesized (PGD2, LTC4, LTD4, LTE4, PAF, cytokines IL-3/-4/-5/-6/-8/-13, GM-CSF, TNF)

Fig. Mediators released by human dermal mast cell degranulation - Dermatology 5e

Preformed Mediators (stored in granules, released immediately)

Mediator	Role in Urticaria
Histamine	Primary mediator; binds H1 receptors on postcapillary venules → vasodilation + increased permeability; acts on sensory nerves → itch
Tryptase	Serine protease; activates bradykinin; used as marker of mast cell activation (serum tryptase)
Chymase	Serine protease; cleaves angiotensin I → angiotensin II; modulates matrix
Heparin	Anticoagulant; binds growth factors; contributes to wheal formation
Chondroitin sulfate	Structural proteoglycan component of granules

Newly Synthesized Mediators (formed after activation from membrane phospholipids)

Mediator	Role
Prostaglandin D2 (PGD2)	Most important eicosanoid; vasodilation + bronchoconstriction
PGE2	Inhibitory - has protective role by inhibiting immunologic mast cell degranulation
Leukotriene C4, D4, E4	= "Slow-reacting substance of anaphylaxis (SRS-A)"; prolonged vasodilation + wheal formation
Platelet-activating factor (PAF)	Platelet aggregation; amplifies wheal formation; especially in cold urticaria
Cytokines: TNF, IL-1β, IL-3, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13	Upregulate endothelial adhesion molecules (ICAM-1, E-selectin); recruit eosinophils, basophils, neutrophils, Th0 cells into lesion
GM-CSF	Promotes eosinophil/basophil survival
BAFF (B-cell activating factor)	Elevated in CSU sera; may sustain autoantibody production

Key downstream effect on vessels: Histamine, TNF, and IL-8 upregulate adhesion molecule expression on endothelial cells → promote migration of circulating inflammatory cells into urticarial lesions.

Dermatology 5e, p. 374
Fitzpatrick's Dermatology, p. 720-721

5. IMMUNOLOGIC MECHANISMS (DETAILED)

5A. Type I Hypersensitivity (IgE-Mediated)

IgE binding to FcεRI diagram showing α1 and α2 subunits of the extracellular domain with IgE, β and γγ transmembrane/cytoplasmic chains

Fig. IgE antibody binding to the high-affinity IgE receptor (FcεRI) - Dermatology 5e

Antigen-specific IgE coats mast cells via FcεRI
Re-exposure to antigen cross-links adjacent FcεRI → degranulation
Symptoms begin 15 min to 1 hour after allergen exposure
Probably accounts for < 10% of all urticaria (mainly acute/episodic forms)
Classic examples: latex contact urticaria, food allergy urticaria (nuts, fish, fruit)

5B. Autoimmune Mechanism (IgG Autoantibodies)

Autoantibody mechanism: IgG anti-FcεRI and anti-IgE autoantibodies activate mast cells/basophils → degranulation → histamine; C5a augments the process; omalizumab blocks free IgE → downregulates FcεRI expression

Fig. Mechanism of mast cell/basophil activation by autoantibodies and omalizumab's mechanism of action - Fitzpatrick's Dermatology

Affects 30-50% of CSU patients (up to 45% by some estimates)
Two types of pathogenic autoantibodies:

Autoantibody	Target	Mechanism
IgG anti-FcεRI (majority)	α subunit of high-affinity IgE receptor	Cross-links FcεRI → mast cell/basophil degranulation
IgG anti-IgE (~10%)	Fc portion of IgE itself	Cross-links IgE bound to FcεRI → degranulation

Anti-FcεRI subtypes:
- Anti-α2 domain: competitive with IgE (blocks binding)
- Anti-α1 domain: non-competitive (binds even in presence of IgE)
Complement amplification: Autoantibody binding → complement activation → C5a anaphylatoxin generated → further augments mast cell degranulation
Detection methods: Autologous serum skin test (ASST), basophil CD63/CD203c activation test, in vitro histamine release assay
IgE autoantibodies also found in CSU against: thyroid peroxidase (TPO), thyroglobulin, tissue factor, IL-24 → these IgE anti-TPO antibodies can produce a local wheal-and-flare, explaining the thyroid disease-urticaria association
Basophils in CSU: Blood basophils are reduced in number and less responsive to anti-IgE stimulus in active disease; responsiveness returns during remission
Omalizumab mechanism: Binds free IgE at its Cε3 domain (receptor binding site) → prevents IgE binding to FcεRI → gradual downregulation of FcεRI expression on mast cells → reduced mast cell "readiness" to degranulate
Dermatology 5e, p. 373-374; Fitzpatrick's Dermatology, p. 720-721; Harrison's 22E

5C. Immune Complex / Complement-Mediated

Urticarial vasculitis and serum-sickness type urticaria
Antigen-antibody complexes deposit in vessel walls → activate complement → C3a + C5a anaphylatoxins → mast cell degranulation AND direct vascular damage
Leads to leukocytoclastic vasculitis histologically

5D. Non-Immunologic (Direct Mast Cell Activation)

Agent	Receptor/Mechanism
Opioids (morphine, codeine)	MRGPRX2 receptor
Substance P	MRGPRX2 receptor
Vancomycin ("red man syndrome")	Direct MRGPRX2
Radiocontrast media	Direct mast cell degranulation
Aspirin / NSAIDs	Shift arachidonic acid to leukotriene pathway (LOX > COX); non-immunologic
Strawberries, lobster	Directly release histamine from mast cells

6. PATHOGENESIS OF SPECIFIC URTICARIA TYPES

Type	Specific Pathological Mechanism
Cholinergic urticaria	Acetylcholine released from cholinergic sympathetic nerves → mast cell activation; ~2/3 have IgE antibodies to MGL_1304 (protein from Malassezia globosa in sweat)
Cold urticaria	Proposed IgE-mediated neoantigen (cold-induced); cryoglobulins (5%); platelet clumping → PAF/platelet factor 4 release; familial form: F12 mutation → bradykinin pathway; FCAS: NLRP3 mutation → IL-1β
Dermatographism	Zonal (piecemeal) mast cell degranulation pattern on electron microscopy; elevated histamine in suction blisters at dermographic sites
Pressure urticaria	Possibly late-phase IgE reaction; no antigen identified
Vibratory urticaria (hereditary)	ADGRE2 missense mutation → destabilizes inhibitory α/β subunit interaction → sensitizes mast cells to vibration-induced degranulation (IgE-independent)
Solar urticaria	Physical stimulus creates neoantigen → reacts with IgE on mast cells; 6 subtypes by action spectrum
Aquagenic urticaria	Water dilutes inhibitory substance in skin → IgE mechanism? Pathomechanism unclear
HAE (not true urticaria)	C1INH deficiency → failure to inhibit factor XII (Hageman factor) and kallikrein → bradykinin excess → vascular permeability (NOT histamine-dependent)

7. VASCULAR PATHOLOGY: HOW THE WHEAL FORMS

Mast cell degranulation
         ↓
Histamine released → binds H1 receptors on postcapillary venules
         ↓
┌─────────────────────────────────────┐
│ Vasodilation of arterioles          │  → ERYTHEMA (red flare)
│ Increased permeability of venules   │  → PLASMA EXTRAVASATION → EDEMA (wheal center pale)
│ Sensory nerve activation (itch)     │  → PRURITUS
└─────────────────────────────────────┘
         ↓
TNF + IL-8 upregulate endothelial adhesion molecules
(ICAM-1, E-selectin, VCAM-1)
         ↓
Eosinophils, basophils, neutrophils, Th0 cells migrate into dermis
         ↓
Late-phase reaction: secondary cytokine release → prolongs/amplifies inflammation

The triple response of Lewis in dermographism demonstrates this perfectly:

Local red reaction (direct vasodilation)
Surrounding flare (axon reflex via sensory nerves)
Wheal (local edema from vascular leakage)

8. ROLE OF COAGULATION IN URTICARIA

A recently recognized pathomechanism in CSU:

Tissue factor is upregulated on eosinophils and monocytes in CSU
Leads to activation of the extrinsic coagulation cascade
Generates thrombin, which can directly activate PAR-1 receptors on mast cells → degranulation
D-dimer levels are elevated in active CSU and correlate with disease severity
This explains why anticoagulants (heparin) may reduce urticaria symptoms

9. SUMMARY TABLE: PATHOLOGY AT A GLANCE

Level	Finding
Gross	Edematous wheal; pale center + red flare; transient (<24h); no scaling
Histology	Superficial dermal edema; splayed collagen bundles; sparse perivascular mixed infiltrate (lymphocytes, eos, basophils, neutrophils); degranulated mast cells
Special stains	Mast cells: Giemsa/toluidine blue (metachromatic granules); tryptase immunostain
Key effector cell	Mast cell (cutaneous MCTC phenotype)
Primary mediator	Histamine (preformed, immediate)
Newly synthesized	PGD2, LTC4/D4/E4, PAF, cytokines (TNF, IL-6, IL-8)
Main receptor	FcεRI (high-affinity IgE receptor) - α1β(γγ) subunit structure
Immunologic trigger	IgE cross-linking (type I HSR) or IgG autoantibodies (anti-FcεRI / anti-IgE)
Non-immunologic trigger	MRGPRX2 agonists (opioids, substance P, codeine)
Autoimmune mechanism	IgG anti-FcεRI or anti-IgE in ~30-50% of CSU; C5a amplifies
Vasculitis variant	Leukocytoclastic vasculitis; fibrinoid necrosis; erythrocyte extravasation

Sources: Dermatology 5e (Grattan, Kocatürk, Saini) | Fitzpatrick's Dermatology Vol. 1-2 | Robbins & Kumar Basic Pathology | Harrison's Principles of Internal Medicine 22E | Andrews' Diseases of the Skin

Explain and elobirate sleep- wake cycle

Finding Sources

Searching Images

sleep wake cycle circadian rhythm suprachiasmatic nucleus diagram

An anatomical diagram and pathophysiology flowchart illustrating the neuroanatomical pathway of the circadian rhythm from the eye to the pineal gland. The visual uses a sagittal section of the human brain and a spinal cord segment to trace the neural signaling cascade triggered by light. The pathway begins at the retina, where light signals travel through the retinohypothalamic tract (RHT) to the suprachiasmatic nucleus (SCN), the master circadian pacemaker. From the SCN, fibers project to the paraventricular nucleus (PVN) of the hypothalamus. The signal descends through the brainstem to the intermediolateral cell column of the upper thoracic spinal cord (T1-T3). Preganglionic sympathetic fibers then ascend to synapse at the superior cervical ganglion (SCG). Finally, postganglionic sympathetic fibers project to the pineal gland to regulate melatonin synthesis. This illustration serves as an educational resource for understanding the sympathetic regulation of the endocrine system and the biological mechanisms of the sleep-wake cycle.

Finding Sources

Loading Image

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Sleep-Wake Cycle: Explained and Elaborated

1. Overview

The sleep-wake cycle is the recurring 24-hour (circadian) pattern of alternating wakefulness and sleep, further subdivided into an ultradian cycle of sleep stages (Non-REM and REM) that repeats roughly every 90 minutes through the night. It is generated by the interaction of two opposing physiological drives:

Circadian drive (wake-promoting, tied to the light-dark cycle via the suprachiasmatic nucleus)
Homeostatic sleep drive (sleep-promoting, builds up with adenosine accumulation during wakefulness)

Ganong's Review of Medical Physiology, 26th Ed., Ch. 14
Stahl's Essential Psychopharmacology, Ch. 10

2. Behavioral States and EEG Correlates

Every state along the spectrum from deep sleep to alert wakefulness has a distinct pattern of brain electrical activity, produced by feedback oscillations within the cortex and between thalamus and cortex.

EEG, EOG, and EMG tracings across wakefulness and sleep stages 1-4 and REM sleep

Fig. 14-8, Ganong's Physiology - EEG/EOG/EMG patterns across the sleep-wake cycle

State	EEG Pattern	Frequency
Awake, relaxed, eyes closed	Alpha rhythm (parietal/occipital)	8-13 Hz
Awake, alert/attentive	Beta rhythm (low voltage, "alpha block"/desynchronization)	13-30 Hz
Stage 1 NREM	Transition; low-voltage mixed frequency; theta rhythm	4-7 Hz
Stage 2 NREM	Sleep spindles + K complexes; reduced muscle tone	7-15 Hz spindles
Stage 3 NREM	High-amplitude delta rhythm begins (slow-wave sleep)	0.5-4 Hz
Stage 4 NREM	Maximum slow-wave activity; deepest sleep	0.5-4 Hz
REM sleep	Rapid, low-voltage EEG (resembles wakefulness); rapid eye movements; near-total loss of skeletal muscle tone	Mixed, fast

Theta and delta rhythms are normal during sleep, but their presence during wakefulness signals brain dysfunction.

Ganong's Physiology, p. 282-283

3. Sleep Architecture: NREM and REM

Non-REM (NREM) Sleep - 4 Stages

Stage 1: Drowsiness/transition from wake to sleep
Stage 2: True sleep onset; spindles and K-complexes; muscle tone reduced
Stage 3-4: Slow-wave sleep (SWS) - deepest, most restorative sleep; marked synchronization of cortical/thalamic activity

REM Sleep

Named for rapid, roving eye movements (recorded as EOG)
Near-complete atonia of skeletal muscles (except eye muscles and diaphragm)
Elevated arousal threshold (harder to wake)
PGO spikes (pontogeniculo-occipital spikes): phasic potentials from pontine cholinergic neurons → lateral geniculate body → occipital cortex
Dreaming occurs predominantly here
PET imaging during REM: ↑ activity in pons, amygdala, anterior cingulate, visual association areas; ↓ activity in prefrontal and parietal cortex - consistent with heightened emotion but disconnection from external orientation
Ganong's Physiology, p. 283
Stahl's Essential Psychopharmacology, p. 429

4. The Ultradian Cycle (Nightly Architecture)

A young adult's typical night:

Enters NREM → progresses through stages 1 → 2 → 3 → 4
Spends 70-100 minutes in stages 3-4
Sleep lightens → first REM period occurs
Cycle repeats at ~90-minute intervals throughout the night
4-6 REM periods occur per night; later cycles have progressively less SWS and more REM

REM Sleep Across the Lifespan

Age Group	% of Total Sleep as REM
Premature infants	~80%
Full-term neonates	~50%
Later childhood onward	Plateaus at ~25%
Elderly	Falls further

Ganong's Physiology, Fig. 14-9, p. 284
Stahl's Essential Psychopharmacology, p. 429

5. Neural Regulation: The Wake-Promoting System

Wakefulness depends on the Ascending Reticular Activating System (ARAS), originating in the central tegmentum of the pons/midbrain, ascending through the thalamus to activate the cerebral cortex diffusely.

Five Key Wake-Promoting Neurotransmitter Systems

Neurotransmitter	Source Nucleus	Projection	Effect
Acetylcholine	Basal forebrain, PPT/LDT (pedunculopontine & laterodorsal tegmental nuclei)	Cortex, thalamus	Cortical activation
Dopamine	Ventral tegmental area (VTA)	Cortical areas	Wakefulness/arousal
Norepinephrine	Locus coeruleus (LC)	Cortical areas	Arousal, alertness
Serotonin	Raphe nuclei (RN)	Basal forebrain, thalamus	Wakefulness stabilization
Histamine	Tuberomammillary nucleus (TMN)	Widespread cortex	Arousal

Orexin/Hypocretin - The Wake "Stabilizer"

Orexin neurons in the lateral/posterior hypothalamus don't directly cause wakefulness but stabilize it by driving all five arousal systems simultaneously:

Orexin → releases ACh from basal forebrain/PPT-LDT
Orexin → releases dopamine from VTA
Orexin → releases norepinephrine from locus coeruleus
Orexin → releases serotonin from raphe nuclei

This is clinically critical: loss of orexin-producing neurons causes narcolepsy (see Section 8).

Stahl's Essential Psychopharmacology, Ch. 10, p. 427-428

6. Neural Regulation: The Sleep-Promoting System

Ventrolateral Preoptic Nucleus (VLPO)

The VLPO (and median preoptic nucleus, MPNO) is the master sleep-promoting center of the hypothalamus.

VLPO neurons contain GABA and galanin
VLPO projects to and inhibits all the wake-promoting centers: TMN, lateral hypothalamus (orexin neurons), basal forebrain, LC, raphe nuclei
By suppressing arousal neurotransmitters, VLPO activation induces sleep

The "Flip-Flop Switch" Model

Sleep and wake are mutually inhibitory: the wake system (orexin/monoamines) inhibits VLPO, while VLPO inhibits the wake system. This creates a bistable switch that flips cleanly between fully awake and fully asleep states (rather than a graded transition), which is why humans normally do not linger in intermediate states.

As light fades in the evening:

Norepinephrine (LC) and serotonin (raphe) provide negative feedback that inhibits orexin release
Loss of orexin de-stabilizes wakefulness
VLPO/GABA takes over, suppressing all arousal neurotransmitters
Sleep is facilitated; melatonin secretion begins
Stahl's Essential Psychopharmacology, p. 428
Kaplan & Sadock's Comprehensive Textbook of Psychiatry
Miller's Anesthesia, 10th Ed.

7. The Two-Process Model of Sleep Regulation

Sleep timing and propensity are governed by two opposing, interacting processes:

Process 1: Homeostatic Sleep Drive (Process S)

Driven by adenosine accumulation in the brain during wakefulness
The longer one is awake, the more adenosine accumulates
Adenosine disinhibits the VLPO → VLPO releases GABA onto the TMN → inhibits wakefulness
Adenosine dissipates during sleep, resetting the drive

Process 2: Circadian Wake Drive (Process C)

Generated by the suprachiasmatic nucleus (SCN), entrained by light input
Promotes wakefulness during the biological day by stimulating orexin release
Independent of prior sleep/wake history

As the day progresses: circadian wake drive gradually diminishes while homeostatic sleep drive rises, until a "tipping point" is reached and sleep is triggered. This explains why sleepiness intensifies through the evening and why jet lag/shift work (which desynchronizes these two processes) cause impaired alertness and sleep disruption.

Stahl's Essential Psychopharmacology, Fig. 10-18, p. 428

8. Circadian Regulation: The SCN-Pineal-Melatonin Axis

Neuroanatomical pathway from retina through RHT to SCN, PVN, spinal cord (T1-T3), superior cervical ganglion, to pineal gland

Fig. Neuroanatomical circadian pathway - retina to pineal gland

The Pathway

Light strikes the retina (specialized melanopsin-containing retinal ganglion cells, independent of rod/cone vision)
Signal travels via the retinohypothalamic tract (RHT) to the suprachiasmatic nucleus (SCN) of the hypothalamus - the body's master circadian pacemaker
SCN projects to the paraventricular nucleus (PVN) of the hypothalamus
Descends through brainstem to the intermediolateral cell column of the upper thoracic spinal cord (T1-T3)
Preganglionic sympathetic fibers ascend to the superior cervical ganglion (SCG)
Postganglionic fibers project to the pineal gland, regulating melatonin synthesis

Key Points

The human circadian clock runs slightly longer than 24 hours; the SCN entrains it to the 24-hour light/dark cycle
Light suppresses melatonin release (signals SCN to tell pineal gland to turn off production)
Melatonin levels rise in the evening as darkness approaches, plateau, then fall as night progresses
Melatonin acts back on MT1 and MT2 receptors in the SCN itself, reinforcing circadian rhythms (a feedback loop)
SCN promotes sleep partly by signaling the sleep-promoting VLPO
Ganong's Physiology, p. 667-678
Harrison's Principles of Internal Medicine 22E, Table 49-1
Tintinalli's Emergency Medicine

9. Respiratory and Autonomic Changes Across the Cycle

During wakefulness: both metabolic and voluntary (behavioral) control systems regulate breathing
During NREM sleep: only the metabolic system operates; ARAS-mediated tonic stimuli to ventilation decrease
During REM sleep: breathing becomes more irregular; loss of muscle tone affects upper airway and intercostal muscles (relevant to obstructive sleep apnea pathophysiology)
Bradley and Daroff's Neurology in Clinical Practice

10. Clinically Relevant Disorders of the Sleep-Wake Cycle

Disorder	Mechanism	Key Features
Narcolepsy	Loss of orexin/hypocretin-producing neurons in hypothalamus (autoimmune, linked to HLA-DR2/DQW1)	Sudden REM-onset sleep, cataplexy, irresistible daytime sleep urges, sleep paralysis
Obstructive Sleep Apnea (OSA)	Reduced upper airway muscle tone during sleep → repeated obstruction	Snoring, apneic episodes >10 sec, fragmented sleep, ↑ stage 1 NREM, ↓ slow-wave sleep; affects ~24% of middle-aged men, ~9% of women
Periodic Limb Movement Disorder (PLMD)	Rhythmic limb movements during NREM sleep	Toe extension/ankle dorsiflexion every 20-90 sec; ↑ stage 1, ↓ stages 3-4

Ganong's Physiology, Clinical Box 14-3, p. 284

11. Summary Diagram (Conceptual)

LIGHT (day) ──► Retina ──► RHT ──► SCN (circadian pacemaker)
                                      │
                    ┌─────────────────┴─────────────────┐
                    ▼                                     ▼
         Orexin/hypocretin (LH)                  Inhibits pineal melatonin
                    │                                     
     ┌──────┬───────┼───────┬────────┐            
     ▼      ▼       ▼       ▼        ▼
    ACh     DA      NE     5-HT   Histamine     ──► WAKEFULNESS
  (basal   (VTA)   (LC)   (Raphe)  (TMN)
  forebrain)

                    ▲  mutual inhibition (flip-flop) ▼

              VLPO/MnPO (GABA + galanin) ──► SLEEP
                    ▲
          Adenosine accumulation (homeostatic drive,
          builds during wakefulness, dissipates in sleep)

DARK (night) ──► SCN releases inhibition ──► Pineal gland ──► Melatonin ↑

Sources: Ganong's Review of Medical Physiology, 26th Edition | Stahl's Essential Psychopharmacology | Harrison's Principles of Internal Medicine, 22nd Edition | Bradley and Daroff's Neurology in Clinical Practice | Kaplan & Sadock's Comprehensive Textbook of Psychiatry | Miller's Anesthesia, 10th Edition

This is a shared conversation. Sign in to Orris to start your own chat.